GlobeNewswire Inc.T3·5mo ago
SLDB Solid Biosciences Inc. Common Stock
XNAS
7.14
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
SLDB
$7.14
—
What changed
Recent filings, trades and movesKey stats
$7.14
- 52-Week Range
- $4.00 – $11.45
- YTD
- +31.10%
- IV Rank (30D)
- 52.22
- Straddle Price
- $3.35
- P/C Vol Ratio
- 0.08
- Market Cap
- $0.7B
- Open
- $6.87
- Day Range
- $6.58 – $7.25
- Volume
- 1,259,953
- Prev Close
- $6.59
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.90% |
| Beta vs SPY | 1.57 |
| Cost of Equity (CAPM) | 13.51% (VRP-adj) |
| WACC | 13.67% |
| Volatility Risk Premium | +101.1pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.2B |
| Return on Equity (TTM) | -55.4% |
| Book / Price | 51.7% — banking bias active (P/B is primary) |
| Debt / Equity | 0.00 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $7.48 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $6.14 |
| Bollinger Width / SMA20 | 22.3% (drives anchor stability) |
| Net Debt | $-0.3B |
| Market Cap | $1B |
Peers used for multiples: ALKS, BIIB, DNTH, DYN, NBIX
(filtered from 8 ETF-co-members; sector bias active)
60-Day Conviction
73%
20-Day Fair Value
≈ by Dec 8, 2026
$7.15
α +0.1%
rank 76%
conviction
11%
40-Day Fair Value
≈ by Jan 6, 2027
$7.38
α +3.4%
rank 81%
conviction
84%
60-Day Fair Value
≈ by Feb 4, 2027
$7.37
α +3.3%
rank 71%
conviction
73%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | median 22.0× · 3 peers |
| Peer P/B | $13.66 | 22% | median 4.0× · 5 peers |
| Peer P/S | n/a | 0% | median 4.3× · 4 peers |
| Market Anchor (SMA50) | $7.48 | 78% | stability 71% (BB-width) |
| Options Expected (B-L 30d) | $6.20 | 0% | 7 strikes · skew +0.30 |
As of 2026-11-09 · updated
Related
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $0.7B
- Employees
- 121
- List Date
- 2018-01-25
- CIK
- 0001707502
- Last Earnings
- Nov 3 · −15.2% vs ±60.6% expected
- Headquarters
- Charlestown, MA
- Homepage
- https://www.solidbio.com
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -16.84% | -31.46% | 34.88% | 10.24% | -18.46% | 18.53% | -0.52% |
| Feb | 22.80% | -36.85% | -25.46% | 32.44% | 77.46% | -3.42% | 11.16% |
| Mar | -35.09% | 49.42% | -13.82% | 36.34% | -27.73% | 16.13% | 4.21% |
| Apr | -6.43% | -54.47% | 2.31% | -28.70% | -3.92% | -1.63% | -15.47% |
| May | -25.93% | 3.64% | 16.82% | -13.42% | -12.05% | 2.95% | -4.67% |
| Jun | -2.40% | 8.04% | -16.83% | -31.27% | 37.57% | 38.94% | 5.67% |
| Jul | -25.99% | 17.19% | -17.43% | 42.26% | 48.70% | -19.44% | 7.55% |
| Aug | -2.17% | -6.45% | -12.59% | 3.36% | -19.77% | 19.45% | -3.03% |
| Sep | -13.09% | -29.30% | -30.39% | -17.71% | 13.63% | -26.82% | -17.28% |
| Oct | -13.98% | -13.67% | -8.98% | -18.58% | -8.18% | -11.17% | -12.43% |
| Nov | -18.22% | 6.35% | 20.00% | -0.87% | 4.42% | 18.83%* | 5.08% |
| Dec | 2.94% | -19.10% | 103.99% | -30.92% | 8.25% | -- | 13.03% |
| Total | -79.57% | -81.02% | -3.59% | -43.02% | 71.05% | 39.05% | -16.18% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $6.16
SMA 50: $7.43
SMA 200: $7.67
Current: $7.13
EMA 12: $6.43
EMA 26: $6.60
MACD: -0.1614 | Signal: 0.1734
BEARISH
ADX (14): 27.16
TREND
+DI: 25.39
−DI: 22.03
Momentum Oscillators
RSI (14): 57.02
NEUTRAL
Stoch %K: 77.97
Stoch %D: 74.95
Williams %R: -7.31
Volume & Volatility
BB Upper: $6.93
BB Lower: $5.38
OVERBOUGHT
OBV: 130,433,026
Vol SMA 20: 1,409,276
Vol ROC: 17.38%
ATR: $0.47
True Range: $0.66
HV 20: 94.4%
HV 30: 78.8%
HV 60: 72.9%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-08T00:00:00 – 2026-11-06T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
Overall Assessment: NEUTRAL (Confidence Level: 6/10)
Key Drivers and Primary Risks:
- Recent positive news headlines highlighting Solid Biosciences' advancements in Duchenne Muscular Dystrophy clinical trial pipeline and FDA designations for Friedreich's Ataxia gene therapy
- High volatility, driven by strong beta (2.03) relative to the market, indicating higher risk and potential for larger price movements
- Strong momentum signals from RSI (58.23) and Stochastic %K (93.60), but MACD (0.07 / Signal: 0.10 / Histogram: -0.04) suggests bearish momentum
Investment Thesis: Solid Biosciences is a high-risk, high-reward biotech company with significant potential for growth, driven by its Duchenne Muscular Dystrophy clinical trial pipeline and FDA designations. However, the stock's recent volatility and mixed technical signals suggest caution and highlight the need to monitor key levels and news sentiment.
Recent News Sentiment Impact: Positive news headlines have contributed to the stock's recent price movements, with a focus on advancements in Duchenne Muscular Dystrophy clinical trial pipeline and FDA designations for Friedreich's Ataxia gene therapy. This positive sentiment is likely driving the stock's overall bullish momentum.
Technical Analysis
Trend Direction: Short-term: NEUTRAL (1-4 weeks), Medium-term: BULLISH (1-3 months), Long-term: BEARISH (3-12 months)
Support/Resistance Levels: Key price levels from moving averages and technical patterns:
- Lower support: $7.57 (Bollinger Bands lower band)
- Upper resistance: $9.36 (Bollinger Bands upper band)
- 20-SMA: $8.46
- 50-SMA: $8.63
Momentum Signals:
- RSI interpretation: Neutral zone (58.23), potential for continued upward momentum
- MACD signal: Bearish momentum, but recent histogram value (-0.04) suggests potential reversal
- Bollinger Bands position: Squeeze, with price near the upper band
Volume Analysis: Volume trends and institutional interest signals:
- Volume SMA 20: 925422.40 (increasing volume)
- OBV: 134781726.15 (strong buying pressure)
- Volume Rate of Change: -38.99% (volume decreasing, but still supportive)
News & Sentiment Analysis
Recent Headlines Summary: Positive news headlines highlighting Solid Biosciences' advancements in Duchenne Muscular Dystrophy clinical trial pipeline and FDA designations for Friedreich's Ataxia gene therapy.
Sentiment Assessment: Aggregate news sentiment is POSITIVE (75% positive, 25% neutral).
Catalyst Identification: Upcoming earnings release, product launches, and regulatory changes.
Market Narrative: News headlines are aligning with the stock's technical signals, driving recent price movements. However, caution is warranted due to high volatility and mixed momentum signals.
Risk & Volatility Assessment
Beta Interpretation: High risk relative to market (beta >1.2).
Volatility Regime: Current vs historical volatility levels:
- Historical: 55.3% (HV20), 61.4% (HV30), 70.7% (HV60)
- Current: 0.80 (high volatility)
Options Market Signals: IV rank: 30.1% (Medium - shows if volatility is historically high/low); current IV: 232.7% (high).
Downside Protection: Support levels and risk management considerations:
- Lower support: $7.57
- Stop-loss levels: 10-15% below current price
Market Context & Positioning
Sector Performance: Relative strength vs sector/market:
- Sector performance: Strong
- Market position: Neutral to bullish
Institutional Activity: Volume patterns suggesting institutional interest:
- Increasing volume on up days, decreasing volume on down days (supportive)
Correlation Analysis: How stock moves relative to market (R-squared interpretation):
- Correlation coefficient: 0.33 (positive correlation)
- R-squared value: 10.2% (low correlation)
Relative Valuation: Position within trading range:
- Trading range: $7.57 - $9.36
- Current price: $9.30
Key Levels & Action Items
Critical Price Levels: Support/resistance to monitor:
- Lower support: $7.57
- Upper resistance: $9.36
- 20-SMA: $8.46
- 50-SMA: $8.63
Breakout/Breakdown Levels: Technical levels that could trigger significant moves:
- Breakout above upper resistance: Bullish momentum
- Breakdown below lower support: Bearish momentum
Time-Sensitive Catalysts: Earnings dates, FDA approvals, product launches:
- Upcoming earnings release (no date available)
- Product launch expectations for Friedreich's Ataxia gene therapy
Risk Management: Stop-loss levels and position sizing considerations:
- Stop-loss levels: 10-15% below current price
- Position sizing: Adjust according to risk tolerance and market conditions
Generated
News
All SLDB news →
GlobeNewswire Inc.T3·10mo ago
GlobeNewswire Inc.T3·11mo ago
GlobeNewswire Inc.T3·11mo ago
GlobeNewswire Inc.T3·12mo ago
GlobeNewswire Inc.T3·15mo ago
GlobeNewswire Inc.T3·17mo ago
GlobeNewswire Inc.T3·23mo ago
Investing.comT3·28mo ago
GlobeNewswire Inc.T3·28mo ago
Showing 1–10 of 50
Page 1 of 5
Earnings History
5 of 8 under expected move
Avg Expected Move
26.29%
Avg Actual Move
15.12%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-03-15 | After-Close | 39.43% | 32.39% | 0.82x | Within |
| 2021-05-14 | After-Close | 22.47% | 1.72% | 0.08x | Within |
| 2021-08-16 | After-Close | 26.72% | 2.79% | 0.10x | Within |
| 2022-04-27 | unknown | 4.56% | 8.63% | 1.89x | Exceeded |
| 2022-08-11 | unknown | 21.40% | 2.73% | 0.13x | Within |
| 2024-01-08 | unknown | 21.51% | 35.29% | 1.64x | Exceeded |
| 2025-02-18 | unknown | 13.68% | 22.08% | 1.61x | Exceeded |
| 2025-11-03 | unknown | 60.58% | 15.29% | 0.25x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
SLDB Options Activity & IV Rank
SLDB IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 226.0%
7-DTE IV: —
Expected Move: $3.35
7-DTE Move: $2.73
Days to Exp: 39 (2026-12-18)
Options Flow · All expiries
Call Volume: 1,243
Put Volume: 97
P/C Volume: 0.078
BULLISH
Call OI: 3,914
Put OI: 582
P/C OI: 0.149
Total OI: 4,496
ATM Options Pricing
ATM Call: $0.90
ATM Put: $2.45
Call %: 12.6%
Put %: 34.3%
Chain Summary
Chain Volume: 1,340
Chain OI: 4,496
Last Updated: 11/9/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 61st percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
61%
vs own history
GEX tilt
+0.65
OI-weighted, today
Vanna tilt
+0.87
δ-sensitivity to IV
Charm tilt
-0.62
δ-decay vs time
Vanna tilt +0.87: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.62: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 7 ATM contracts, 0k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)
IV Rank (30 DTE)52.2MediumNov 9
Straddle Price (30 DTE)$3.35Nov 9
Beta Analysis
Risk Metrics
Beta: 2.0427
Alpha: 59.98%
Correlation: 0.3644
R-Squared: 13.3%
Stock Volatility: 77.2%
Market Volatility: 13.8%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own SLDB
4 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $28.1M | #967 of 6285 | +8.4% | 13F | |
| Point72 Hedge fund Steve Cohen | $4.5M | #1011 of 1945 | -78.2% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $820K | #2404 of 3138 | -33.9% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $19K | #3741 of 4729 | -24.8% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
SLDB Institutional Ownership (13F)
Filings for 2026-06-30 · 43 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 96,468,531 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
4 filers$1.71M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Goldman Sachs Group Inc Custodian | $999.00K | 58.39% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $373.63K | 21.84% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $308.69K | 18.04% | 2026-06-30 |
| 4 | Simplex Trading, LLC Custodian | $29.64K | 1.73% | 2026-09-30 |
2 filers$134.31K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $132.87K | 98.92% | 2026-06-30 |
| 2 | Simplex Trading, LLC Custodian | $1.45K | 1.08% | 2026-09-30 |
SLDB Insider Trading (Form 4)
Latest: 2026-10-26Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-26 | Ilan Ganot | Director | Grant (A) | +150,000 RSU | — | EDGAR | |
| 2026-10-20 | Gabriel Brooks | Chief Medical Officer | Mixed Exer +9,750 · Sell −4,374 |
+5,376 | $5.62 | -$24.6K | EDGAR |
| 2026-10-06 | Ian F Smith | Director | Exer (M) | +3,440 | — | EDGAR | |
| 2026-07-07 | Ian F Smith | Director | Exer (M) | +3,440 | — | EDGAR | |
| 2026-06-11 | Martin I Freed | Director | Grant (A) | +77,500 opt | — | EDGAR | |
| 2026-06-11 | Adam Leo Stone | Director | Grant (A) | +77,500 opt | — | EDGAR | |
| 2026-06-11 | Ian F Smith | Director | Grant (A) | +77,500 opt | — | EDGAR | |
| 2026-06-11 | Clare Kahn | Director | Grant (A) | +77,500 opt | — | EDGAR | |
| 2026-06-11 | Sukumar Nagendran | Director | Grant (A) | +77,500 opt | — | EDGAR | |
| 2026-06-11 | Georgia Keresty | Director | Grant (A) | +77,500 opt | — | EDGAR | |
| 2026-06-11 | Lynne Marie Sullivan | Director | Grant (A) | +77,500 opt | — | EDGAR | |
| 2026-06-11 | PERCEPTIVE ADVISORS LLC | Director | Grant (A) | +77,500 opt | — | EDGAR | |
| 2026-06-11 | Ilan Ganot | Director | Grant (A) | +77,500 opt | — | EDGAR | |
| 2026-04-21 | Gabriel Brooks | Chief Medical Officer | Grant (A) | +58,847 RSU | — | EDGAR | |
| 2026-04-21 | Paul Herzich | Chief Technology Officer | Grant (A) | +54,925 RSU | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
SLDB Insider Holdings
17 insiders · @ $7.13
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Bain Capital Life Sciences Fund II, L.P. | 10%+ Owner | 5,034,582 | $35.92M | $4.03M | 1 | 2025-02-21 |
| 2 | Adage Capital Management, L.P. | 10%+ Owner | 4,248,084 | $30.31M | $1.91M | 1 | 2025-02-19 |
| 3 | PERCEPTIVE LIFE SCIENCES MASTER FUND LTD | Director | 449,987 | $3.21M | $29.67M | 4 | 2025-06-13 |
| 4 | Alexander Cumbo | President and CEO | 235,405 | $1.68M | -$1.12M | 12 | 2026-04-21 |
| 5 | Ian F Smith | Director | 141,585 | $1.01M | $0 | 31 | 2026-10-06 |
| 6 | Ilan Ganot | Director | 129,429 | $923.5K | -$1.76M | 45 | 2026-10-26 |
| 7 | RA CAPITAL MANAGEMENT, L.P. | Director | 109,661 | $782.4K | $5.00M | 3 | 2025-02-21 |
| 8 | David T Howton | Chief Operating Officer | 105,077 | $749.7K | -$498.9K | 12 | 2026-04-21 |
| 9 | Kevin Tan | CFO & Treasurer | 104,826 | $747.9K | -$390.2K | 12 | 2026-04-21 |
| 10 | Gabriel Brooks | Chief Medical Officer | 97,241 | $693.8K | -$337.4K | 12 | 2026-10-20 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
SLDB Board & Officers
As of SEC filings through Oct 26, 2026Directors 12
- Adam Leo Stone · since Jan 25, 2018
- Ilan Ganot · since Jan 25, 2018
- Lynne Marie Sullivan · since Jan 25, 2018
- Perceptive Advisors LLC (entity) · since Jan 25, 2018
- Perceptive Life Sciences Master Fund Ltd (entity) · since Jan 25, 2018
- Martin I Freed · since Jun 22, 2018
- Sukumar Nagendran · since Sep 12, 2018
- Ian F Smith · since Apr 15, 2020
- Clare Kahn · since Mar 2, 2021
- Georgia Keresty · since Mar 2, 2021
- Joseph Edelman · listed since Mar 2021
- Alexander Cumbo · since Dec 2, 2022
Officers 6
- Alexander Cumbo · President and CEO · since Dec 2, 2022
- Kevin Tan · CFO & Treasurer · since Jan 9, 2023
- David T Howton · Chief Operating Officer · listed since Dec 2023
- Jessie Hanrahan · Chief Regulatory Officer · since Dec 2, 2022
- Paul Herzich · Chief Technology Officer · since Dec 2, 2022
- Gabriel Brooks · Chief Medical Officer · since Oct 18, 2023
10% owners 7
- Joseph Edelman · since Jan 25, 2018
- Perceptive Advisors LLC (entity) · since Jan 25, 2018
- Perceptive Life Sciences Master Fund Ltd (entity) · since Jan 25, 2018
- Peter Kolchinsky · listed since Jun 2026
- RA Capital Healthcare Fund LP (entity) · listed since Jun 2026
- Ra Capital Management, L.p. (entity) · listed since Jun 2026
- Rajeev M. Shah · listed since Jun 2026
Changes in the last 10 years (139)
| Jun 24, 2026 | Rajeev M. Shah first listed as a 10% owner in an SEC filing |
| Jun 24, 2026 | Ra Capital Management, L.p. first listed as a 10% owner in an SEC filing |
| Jun 24, 2026 | RA Capital Healthcare Fund LP first listed as a 10% owner in an SEC filing |
| Jun 24, 2026 | Peter Kolchinsky first listed as a 10% owner in an SEC filing |
| Feb 21, 2025 | Rajeev M. Shah reported in an SEC filing no longer being a director |
| Feb 21, 2025 | Rajeev M. Shah reported in an SEC filing no longer being a 10% owner |
| Feb 21, 2025 | Ra Capital Management, L.p. reported in an SEC filing no longer being a director |
| Feb 21, 2025 | Ra Capital Management, L.p. reported in an SEC filing no longer being a 10% owner |
| Feb 21, 2025 | RA Capital Healthcare Fund LP reported in an SEC filing no longer being a director |
| Feb 21, 2025 | RA Capital Healthcare Fund LP reported in an SEC filing no longer being a 10% owner |
| Feb 21, 2025 | Peter Kolchinsky reported in an SEC filing no longer being a director |
| Feb 21, 2025 | Peter Kolchinsky reported in an SEC filing no longer being a 10% owner |
| Feb 21, 2025 | Bain Capital Life Sciences Partners, LP reported in an SEC filing no longer being a director |
| Feb 21, 2025 | Bain Capital Life Sciences Partners, LP reported in an SEC filing no longer being a 10% owner |
| Feb 21, 2025 | Bain Capital Life Sciences Investors, LLC reported in an SEC filing no longer being a director |
| Feb 21, 2025 | Bain Capital Life Sciences Investors, LLC reported in an SEC filing no longer being a 10% owner |
| Feb 21, 2025 | Bain Capital Life Sciences Investors II, LLC reported in an SEC filing no longer being a director |
| Feb 21, 2025 | Bain Capital Life Sciences Investors II, LLC reported in an SEC filing no longer being a 10% owner |
| Feb 21, 2025 | Bain Capital Life Sciences Fund II, L.P. reported in an SEC filing no longer being a director |
| Feb 21, 2025 | Bain Capital Life Sciences Fund II, L.P. reported in an SEC filing no longer being a 10% owner |
| Feb 21, 2025 | BCLS SB Investco, LP reported in an SEC filing no longer being a director |
| Feb 21, 2025 | BCLS SB Investco, LP reported in an SEC filing no longer being a 10% owner |
| Feb 21, 2025 | BCLS II Investco, LP reported in an SEC filing no longer being a director |
| Feb 21, 2025 | BCLS II Investco, LP reported in an SEC filing no longer being a 10% owner |
| Feb 21, 2025 | BCLS II Investco (GP), LLC reported in an SEC filing no longer being a director |
| Feb 21, 2025 | BCLS II Investco (GP), LLC reported in an SEC filing no longer being a 10% owner |
| Feb 21, 2025 | BCLS II Equity Opportunities, LP reported in an SEC filing no longer being a director |
| Feb 21, 2025 | BCLS II Equity Opportunities, LP reported in an SEC filing no longer being a 10% owner |
| Feb 21, 2025 | BCLS II Equity Opportunities GP, LLC reported in an SEC filing no longer being a director |
| Feb 21, 2025 | BCLS II Equity Opportunities GP, LLC reported in an SEC filing no longer being a 10% owner |
| Feb 21, 2025 | BCIP Life Sciences Associates, LP reported in an SEC filing no longer being a director |
| Feb 21, 2025 | BCIP Life Sciences Associates, LP reported in an SEC filing no longer being a 10% owner |
| Feb 19, 2025 | Robert Atchinson reported in an SEC filing no longer being a 10% owner |
| Feb 19, 2025 | Phillip Gross reported in an SEC filing no longer being a 10% owner |
| Feb 19, 2025 | Adage Capital Management, L.P. reported in an SEC filing no longer being a 10% owner |
| Feb 18, 2025 | Robert Atchinson became a 10% owner |
| Feb 18, 2025 | Phillip Gross became a 10% owner |
| Feb 18, 2025 | Adage Capital Management, L.P. became a 10% owner |
| Jun 7, 2024 | The company announced the departure of Adam Koppel from the board in an SEC filing |
| Jan 12, 2024 | Bain Capital Life Sciences Partners, LP first listed as a director in an SEC filing |
| Jan 12, 2024 | Bain Capital Life Sciences Investors, LLC first listed as a director in an SEC filing |
| Jan 12, 2024 | Bain Capital Life Sciences Investors II, LLC first listed as a director in an SEC filing |
| Jan 12, 2024 | Bain Capital Life Sciences Fund II, L.P. first listed as a director in an SEC filing |
| Jan 12, 2024 | BCLS SB Investco, LP first listed as a director in an SEC filing |
| Jan 12, 2024 | BCLS II Investco, LP first listed as a director in an SEC filing |
| Jan 12, 2024 | BCLS II Investco (GP), LLC first listed as a director in an SEC filing |
| Jan 12, 2024 | BCIP Life Sciences Associates, LP first listed as a director in an SEC filing |
| Jan 11, 2024 | BCLS II Equity Opportunities, LP became a director |
| Jan 11, 2024 | BCLS II Equity Opportunities, LP became a 10% owner |
| Jan 11, 2024 | BCLS II Equity Opportunities GP, LLC became a director |
| Jan 11, 2024 | BCLS II Equity Opportunities GP, LLC became a 10% owner |
| Dec 5, 2023 | Jennifer Marlowe listed as Cso (previously CSO, FA & Cardiac) in SEC filings |
| Dec 5, 2023 | David T Howton listed as Chief Operating Officer (previously Chief Admin Officer and Secretary) in SEC filings |
| Oct 18, 2023 | Gabriel Brooks became Chief Medical Officer |
| May 22, 2023 | The company announced the departure of Carl Ashley Morris as Chief Scientific Officer in an SEC filing |
| Jan 9, 2023 | Kevin Tan became CFO & Treasurer |
| Dec 6, 2022 | Perceptive Xontogeny Venture Fund, LP first on file as a director |
| Dec 6, 2022 | Perceptive Xontogeny Venture Fund, LP first on file as a 10% owner |
| Dec 6, 2022 | Perceptive Venture Advisors, LLC first on file as a director |
| Dec 6, 2022 | Perceptive Venture Advisors, LLC first on file as a 10% owner |
| Dec 5, 2022 | RA Capital Nexus Fund, L.P. first on file as a director |
| Dec 5, 2022 | RA Capital Nexus Fund, L.P. first on file as a 10% owner |
| Dec 5, 2022 | Adam Koppel first listed as a 10% owner in an SEC filing |
| Dec 2, 2022 | Paul Herzich became Chief Technology Officer |
| Dec 2, 2022 | Jessie Hanrahan became Chief Regulatory Officer |
| Dec 2, 2022 | Jennifer Marlowe became CSO, FA & Cardiac |
| Dec 2, 2022 | David T Howton became Chief Admin Officer and Secretary |
| Dec 2, 2022 | Bain Capital Life Sciences Partners, LP became a 10% owner |
| Dec 2, 2022 | Bain Capital Life Sciences Investors, LLC became a 10% owner |
| Dec 2, 2022 | Bain Capital Life Sciences Investors II, LLC became a 10% owner |
| Dec 2, 2022 | Bain Capital Life Sciences Fund II, L.P. became a 10% owner |
| Dec 2, 2022 | BCLS SB Investco, LP became a 10% owner |
| Dec 2, 2022 | BCLS II Investco, LP became a 10% owner |
| Dec 2, 2022 | BCLS II Investco (GP), LLC became a 10% owner |
| Dec 2, 2022 | BCIP Life Sciences Associates, LP became a 10% owner |
| Dec 2, 2022 | Alexander Cumbo became a director |
| Dec 2, 2022 | Alexander Cumbo became President and CEO |
| Sep 29, 2022 | The company announced the departure of Ilan Ganot as CEO & President in an SEC filing |
| Sep 29, 2022 | The company announced the departure of Erin Powers Brennan as Chief Legal Officer, Secretary in an SEC filing |
| Apr 22, 2022 | The company announced the departure of Joel Solomon Zev Schneider as Chief Operating Officer in an SEC filing |
| Mar 23, 2021 | Joseph Edelman first listed as a director in an SEC filing |
| Mar 4, 2021 | Joel Solomon Zev Schneider listed as Chief Operating Officer (previously Chief Technology Officer) in SEC filings |
| Mar 2, 2021 | Georgia Keresty became a director |
| Mar 2, 2021 | Clare Kahn became a director |
| Mar 1, 2021 | Erin Powers Brennan became Chief Legal Officer, Secretary |
| Jan 29, 2021 | Stephen J. DiPalma became Interim CFO |
| Dec 14, 2020 | Rajeev M. Shah first listed as a 10% owner in an SEC filing |
| Dec 10, 2020 | Ra Capital Management, L.p. became a director |
| Dec 10, 2020 | Ra Capital Management, L.p. became a 10% owner |
| Dec 10, 2020 | RA Capital Healthcare Fund LP became a director |
| Dec 10, 2020 | RA Capital Healthcare Fund LP became a 10% owner |
| Dec 10, 2020 | Peter Kolchinsky became a director |
| Dec 10, 2020 | Peter Kolchinsky became a 10% owner |
| Oct 22, 2020 | Ultragenyx Pharmaceutical Inc. became a 10% owner |
| Apr 15, 2020 | Ian F Smith became a director |
| Jan 29, 2020 | Lynette Herscha listed as Chief Legal Officer (previously See Remark) in SEC filings |
| Jan 29, 2020 | Joel Solomon Zev Schneider listed as Chief Technology Officer (previously Chief Technology Officer and Head of Exploratory Research and Development) in SEC filings |
| Jan 29, 2020 | Jennifer Lynn Ziolkowski listed as CFO, Treasurer & Asst. Secy (previously Chief Financial Officer, Treasurer and Assistant Secretary) in SEC filings |
| Mar 28, 2019 | Boxer Capital, LLC reported in an SEC filing no longer being a 10% owner |
| Mar 4, 2019 | MVA Investors, LLC became a 10% owner |
| Mar 4, 2019 | Joseph Lewis became a 10% owner |
| Mar 4, 2019 | Braslyn Ltd. became a 10% owner |
| Mar 4, 2019 | Boxer Capital, LLC became a 10% owner |
| Mar 4, 2019 | Boxer Asset Management Inc. became a 10% owner |
| Jan 30, 2019 | Lynette Herscha became See Remark |
| Sep 12, 2018 | Sukumar Nagendran became a director |
| Aug 28, 2018 | Gilad David Hayeem reported in an SEC filing no longer being a director |
| Aug 28, 2018 | Gilad David Hayeem reported in an SEC filing no longer being a 10% owner |
| Aug 28, 2018 | Gilad David Hayeem reported in an SEC filing no longer being President |
| Jul 26, 2018 | Matthew Bennett Arnold no longer listed as a 10% owner in SEC filings |
| Jul 26, 2018 | Ilan Ganot listed as CEO & President (previously Chief Executive Officer) in SEC filings |
| Jun 22, 2018 | Martin I Freed became a director |
| Jan 31, 2018 | JPMORGAN CHASE & CO reported in an SEC filing no longer being a 10% owner |
| Jan 31, 2018 | JPMC Strategic Investments II Corp reported in an SEC filing no longer being a 10% owner |
| Jan 25, 2018 | Robert Luther Huffines became a director |
| Jan 25, 2018 | Rajeev M. Shah became a director |
| Jan 25, 2018 | Perceptive Life Sciences Master Fund Ltd became a director |
| Jan 25, 2018 | Perceptive Life Sciences Master Fund Ltd became a 10% owner |
| Jan 25, 2018 | Perceptive Advisors LLC became a director |
| Jan 25, 2018 | Perceptive Advisors LLC became a 10% owner |
| Jan 25, 2018 | Pedro Alvaro Amorrortu became Chief Operating Officer |
| Jan 25, 2018 | Matthew Bennett Arnold became a director |
| Jan 25, 2018 | Matthew Bennett Arnold became a 10% owner |
| Jan 25, 2018 | Lynne Marie Sullivan became a director |
| Jan 25, 2018 | Juan Andrey Zarur became a director |
| Jan 25, 2018 | Joseph Edelman became a 10% owner |
| Jan 25, 2018 | Jorge Armando Quiroz became Chief Medical Officer |
| Jan 25, 2018 | Joel Solomon Zev Schneider became Chief Technology Officer and Head of Exploratory Research and Development |
| Jan 25, 2018 | Jennifer Lynn Ziolkowski became Chief Financial Officer, Treasurer and Assistant Secretary |
| Jan 25, 2018 | JPMORGAN CHASE & CO became a 10% owner |
| Jan 25, 2018 | JPMC Strategic Investments II Corp became a 10% owner |
| Jan 25, 2018 | Ilan Ganot became a director |
| Jan 25, 2018 | Ilan Ganot became Chief Executive Officer |
| Jan 25, 2018 | Gilad David Hayeem became a director |
| Jan 25, 2018 | Gilad David Hayeem became a 10% owner |
| Jan 25, 2018 | Gilad David Hayeem became President |
| Jan 25, 2018 | Carl Ashley Morris became Chief Scientific Officer |
| Jan 25, 2018 | Adam Leo Stone became a director |
| Jan 25, 2018 | Adam Koppel became a director |
Not reported recently (18)
- Perceptive Xontogeny Venture Fund, LP · Last reported as a director in an SEC filing dated Feb 21, 2025
- Jennifer Marlowe · Last reported as Cso in an SEC filing dated Feb 16, 2024
- Adam Koppel · Last reported as a 10% owner in an SEC filing dated Jan 12, 2024
- RA Capital Nexus Fund, L.P. · Last reported as a director in an SEC filing dated Jan 12, 2024
- Robert Luther Huffines · Last reported as a director in an SEC filing dated Dec 15, 2022
- Perceptive Venture Advisors, LLC · Last reported as a director in an SEC filing dated Dec 6, 2022
- Stephen J. DiPalma · Last reported as Interim CFO in an SEC filing dated Feb 1, 2021
- Jennifer Lynn Ziolkowski · Last reported as CFO, Treasurer & Asst. Secy in an SEC filing dated Jan 29, 2021
- Matthew Bennett Arnold · Last reported as a director in an SEC filing dated Dec 14, 2020
- Ultragenyx Pharmaceutical Inc. · Last reported as a 10% owner in an SEC filing dated Oct 30, 2020
- Lynette Herscha · Last reported as Chief Legal Officer in an SEC filing dated Jul 29, 2020
- Juan Andrey Zarur · Last reported as a director in an SEC filing dated Jan 3, 2020
- Joseph Lewis · Last reported as a 10% owner in an SEC filing dated Mar 6, 2019
- Braslyn Ltd. · Last reported as a 10% owner in an SEC filing dated Mar 6, 2019
- MVA Investors, LLC · Last reported as a 10% owner in an SEC filing dated Mar 6, 2019
- Boxer Asset Management Inc. · Last reported as a 10% owner in an SEC filing dated Mar 6, 2019
- Jorge Armando Quiroz · Last reported as Chief Medical Officer in an SEC filing dated Jan 25, 2019
- Pedro Alvaro Amorrortu · Last reported as Chief Operating Officer in an SEC filing dated Jan 25, 2019
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
SLDB Proposed Insider Sales (Form 144)
Latest: 2026-02-18
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-02-18 | Brooks Gabriel | Officer | 5,563 | $32.4K | 2026-02-18 | ETRADE FINANCIAL CORPORATION | 10b5-1 | EDGAR |
| 2026-02-18 | Cumbo Alexander | Officer, Director | 16,644 | $96.9K | 2026-02-18 | ETRADE FINANCIAL CORPORATION | 10b5-1 | EDGAR |
| 2026-02-18 | Hanrahan Jessie | Officer | 4,134 | $24.1K | 2026-02-18 | ETRADE FINANCIAL CORPORATION | 10b5-1 | EDGAR |
| 2026-02-18 | Herzich Paul | Officer | 3,616 | $21.1K | 2026-02-18 | ETRADE FINANCIAL CORPORATION | 10b5-1 | EDGAR |
| 2026-02-18 | Ganot Ilan | Director | 2,658 | $15.7K | 2026-02-18 | ETRADE FINANCIAL CORPORATION | 10b5-1 | EDGAR |
| 2026-02-18 | Howton David T | Officer | 7,469 | $43.5K | 2026-02-18 | ETRADE FINANCIAL CORPORATION | 10b5-1 | EDGAR |
| 2026-02-18 | Tan Kevin | Officer | 5,404 | $31.5K | 2026-02-18 | ETRADE FINANCIAL CORPORATION | 10b5-1 | EDGAR |
| 2026-02-04 | Tan Kevin | Officer | 14,783 | $95.2K | 2026-02-04 | ETRADE FINANCIAL CORPORATION | 10b5-1 | EDGAR |
| 2026-02-04 | Herzich Paul | Officer | 10,905 | $70.2K | 2026-02-04 | ETRADE FINANCIAL CORPORATION | 10b5-1 | EDGAR |
| 2026-02-04 | Ganot Ilan | Director | 7,205 | $46.4K | 2026-02-04 | ETRADE FINANCIAL CORPORATION | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-04
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
ETF Holders
47 ETFs hold SLDB
25 shown · $82.35M total exposure · 0.02% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $22.8M | — | 2026-09-30 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.02% | $12.9M | $76.6B | 2026-11-06 |
| 3 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 0.11% | $11.2M | $10.0B | 2026-11-05 |
| 4 | VXF Vanguard Extended Market ETF | Vanguard | 0.01% | $5.3M | — | 2026-09-30 |
| 5 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.04% | $4.3M | $11.1B | 2026-11-06 |
| 6 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.01% | $3.9M | — | 2026-11-05 |
| 7 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.05% | $3.3M | $6.6B | 2026-11-05 |
| 8 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.02% | $3.2M | — | 2026-09-30 |
| 9 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.02% | $2.4M | $13.9B | 2026-11-06 |
| 10 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.02% | $2.3M | $13.7B | 2026-11-06 |
| 11 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.13% | $1.5M | $1.2B | 2026-11-06 |
| 12 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.02% | $1.2M | — | 2026-11-05 |
| 13 | VHT Vanguard Health Care ETF | Vanguard | 0.01% | $1.2M | — | 2026-09-30 |
| 14 | SBIO ALPS Medical Breakthroughs ETF | Nport | 0.49% | $1.2M | — | 2026-08-31 |
| 15 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.00% | $940,163 | — | 2026-11-05 |
| 16 | PRFZ Invesco RAFI US 1500 Small-Mid ETF | Nport | 0.03% | $779,426 | — | 2026-07-31 |
| 17 | DCOR Dimensional US Core Equity 1 ETF | Dimensional | 0.00% | $763,471 | — | 2026-11-05 |
| 18 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $743,174 | $93.2B | 2026-11-06 |
| 19 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.02% | $669,529 | $3.2B | 2026-11-05 |
| 20 | LABU Direxion Daily S&P Biotech Bull 3X ETF | Direxion | 0.08% | $402,887 | — | 2026-11-06 |
| 21 | VFMO Vanguard U.S. Momentum Factor ETF | Vanguard | 0.02% | $381,386 | — | 2026-11-05 |
| 22 | BBC Virtus Biotech Clinical Trials Etf | Nport | 0.76% | $350,860 | — | 2026-07-31 |
| 23 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.02% | $288,759 | — | 2026-09-30 |
| 24 | DXUV Dimensional US Vector Equity ETF | Dimensional | 0.00% | $281,073 | — | 2026-11-05 |
| 25 | VTWV Vanguard Russell 2000 Value ETF | Vanguard | 0.02% | $257,439 | — | 2026-09-30 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-1.95
TTM Revenue
—
TTM Net Income
$-191.78M
TTM Op. Cash Flow
$-171.67M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q1 '26 | 2026-03-31 | — | $-56.74M | $-0.52 | $-47.23M |
| Q4 '25 | 2025-12-31 | — | $-49.79M | $-0.53 | $-53.55M |
| Q3 '25 | 2025-09-30 | — | $-45.78M | $-0.48 | $-33.47M |
| Q2 '25 | 2025-06-30 | — | $-39.48M | $-0.42 | $-37.41M |
| Q1 '25 | 2025-03-31 | — | $-39.28M | $-0.59 | $-31.85M |
| Q4 '24 | 2024-12-31 | — | $-42.60M | $-1.02 | $-29.64M |
| Q3 '24 | 2024-09-30 | — | $-32.73M | $-0.79 | $-23.71M |
| Q2 '24 | 2024-06-30 | — | $-25.07M | $-0.61 | $-21.47M |
| Q1 '24 | 2024-03-31 | — | $-24.30M | $-0.64 | $-25.19M |
| Q4 '23 | 2023-12-31 | — | $-20.34M | $-1.00 | $-20.82M |
| Q3 '23 | 2023-09-30 | — | $-20.98M | $-1.05 | $-17.90M |
| Q2 '23 | 2023-06-30 | — | $-24.63M | $-1.25 | $-27.46M |
Q1 2026 • period ending 2026-03-31 • filed 2026-05-12
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
1.84
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-51.3%
ROA
-45.3%
Div Yield
0.00%
FCF Yield
-24.96%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$687.82M
as of 2026-11-09
SLDB vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| MRNA Moderna, Inc. Common Stock | $101.5B | — | −27.6% | +804.0% | 51 |
| BIIB Biogen Inc. Common Stock | $36.7B | 110.3 | +2.3% | +45.2% | 100 |
| NBIX Neurocrine Biosciences Inc | $16.7B | 25.0 | +38.0% | +19.9% | 31 |
| ALKS Alkermes Inc. plc | $7.7B | — | +15.3% | +65.1% | 18 |
| PTCT PTC Therapeutics, Inc. | $5.5B | — | −35.1% | −15.0% | 12 |
| EWTX Edgewise Therapeutics, Inc. Common Stock | $4.9B | — | — | +98.4% | 58 |
| DNTH Dianthus Therapeutics, Inc. Common Stock | $4.8B | — | −60.8% | +128.8% | 76 |
| DYN Dyne Therapeutics, Inc. Common Stock | $3.4B | — | — | +1.5% | 86 |
| SLDB Solid Biosciences Inc. Common Stock | $736M | — | — | +30.9% | 52 |
| Peer median | $6.6B | 67.7 | −12.7% | +55.1% | 54 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
12.30M
SI % of Float
17.75%
Days to Cover
8.52
Short Vol Ratio
67.7%
Free Float
69.29M
Float %
64.6%
Short interest 2026-10-15 • Short volume 2026-11-06 • Float 2026-08-14